search
Back to results

Reduction Bleeding in Laminectomy With Double Doses of Tranexamic Acid

Primary Purpose

Bleeding

Status
Completed
Phase
Phase 4
Locations
Thailand
Study Type
Interventional
Intervention
tranexamic acid
0.9% NaCl
Sponsored by
Mahidol University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bleeding focused on measuring tranexamic acid, bleeding, blood transfusion, spine surgery

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • has laminectomy with instrumentation or equal or more than 3 levels laminectomy
  • age 18-65 years
  • ASA 1-3
  • elective operation

Exclusion Criteria:

  • allergy to tranexamic acid
  • anemia (Hb<12 g/dl in female or Hb<13 g/dl in male)
  • history of CVT, IHD, PE, strokes
  • liver disease
  • chronic kidney disease with creatinie>2.0 mg/dl
  • receive anticoagulant or coagulopathy

Sites / Locations

  • Manee Raksakietisak

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

tranexamic acid

0.9% NaCl

Arm Description

Tranexamic acid (15 mg/kg in 0.9% NaCl and the total volume is 100 ml) will given before induction and the second dose(15 mg/kg in 0.9% NaCl and the total volume is 100 ml) will be given at 3 hours after the first dose.

0.9% NaCl 100 ml will be given as a placebo before induction and 3 hours after the first dose

Outcomes

Primary Outcome Measures

perioperative blood loss
Intraoperative and postoperative blood loss will be measured by from swab, suction and vaccum drainage

Secondary Outcome Measures

perioperative blood transfusion
When the blood loss more than acceptable and the hematocrit below 30%, the packed red cell will be given.

Full Information

First Posted
July 16, 2012
Last Updated
December 17, 2013
Sponsor
Mahidol University
search

1. Study Identification

Unique Protocol Identification Number
NCT01643135
Brief Title
Reduction Bleeding in Laminectomy With Double Doses of Tranexamic Acid
Official Title
Reduction Perioperative Bleeding in Laminectomy With Instrumentation or More Than or Equal to 3 Levels Laminectomy: The Comparison Between Placebo, and Double Doses of Tranexamic Acid (15 mg/kg and 15 mg/kg)
Study Type
Interventional

2. Study Status

Record Verification Date
December 2013
Overall Recruitment Status
Completed
Study Start Date
June 2012 (undefined)
Primary Completion Date
December 2013 (Actual)
Study Completion Date
December 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mahidol University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Tranexamic acid has benn widely used to reduce perioperative bleeding in several operations such as cardiac surgery, liver transplant and joint arthroplasty with good results. Few studies in laminectomy had conflicting results and varying in doses. The objective is to compare perioperative bleeding in major laminectomy between patients receive doubles doses of tranexamic acids (15 mg/kg and 15 mg/kg) with who receive pacebo (0.9% NaCl).
Detailed Description
78 patients undergoing major laminectomy (with instrumentation or equal or more than 3 levels laminectomy) will be enrolled. We exclude patients who age over 65, anemia, allergy to tranexamic acid, history of deep vein thormbosis (DVT), ischemic heart disease (IHD), pulmonary embolism (PE), strokes, liver disease, chronic kidney disease with creatinine >2.0 mg/dl, and coagulopathy. After randomization, before induction and 3 hour after the first dose, patients will receive study drug or placebo intravenously. The standard anesthesia and monitoring will be tha same for all of the patients. Perioperative mild hypotensive technique will be used with the mean arterial pressure more than 60 mmHg and nearly the end, the blood pressure will be back to normal for the bleeding check. Hematocrit will be monitored at the begining and every two hours. Blood will be given if the hematocrit is below 30%. The perioperative fluid will be managed by anesthesiologist who will not know the patients' groups. The next morning, the hematocrit and blood creatinine will be checked and if the hematocrit is lower than 30%, blood will be given. Perioperative blood loss, total fluid and blood transfusion within 24 hours will be recorded. If there are any suspected symptoms and signs of DVT, angina, CHF, PE, strokes or other complications, the necessory investigations will be done for the definite dignosis and the appropriate treatment will be started immediately.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bleeding
Keywords
tranexamic acid, bleeding, blood transfusion, spine surgery

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
78 (Actual)

8. Arms, Groups, and Interventions

Arm Title
tranexamic acid
Arm Type
Active Comparator
Arm Description
Tranexamic acid (15 mg/kg in 0.9% NaCl and the total volume is 100 ml) will given before induction and the second dose(15 mg/kg in 0.9% NaCl and the total volume is 100 ml) will be given at 3 hours after the first dose.
Arm Title
0.9% NaCl
Arm Type
Placebo Comparator
Arm Description
0.9% NaCl 100 ml will be given as a placebo before induction and 3 hours after the first dose
Intervention Type
Drug
Intervention Name(s)
tranexamic acid
Other Intervention Name(s)
transamine (Daiichi-Sankyo, Japan)
Intervention Description
Transamine acts as antifibrinolysis which looks alike 0.9% NaCl (placebo)
Intervention Type
Drug
Intervention Name(s)
0.9% NaCl
Other Intervention Name(s)
NSS
Intervention Description
0.9% NaCL (NSS) is clear fluid which looks alike tranexamic acid
Primary Outcome Measure Information:
Title
perioperative blood loss
Description
Intraoperative and postoperative blood loss will be measured by from swab, suction and vaccum drainage
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
perioperative blood transfusion
Description
When the blood loss more than acceptable and the hematocrit below 30%, the packed red cell will be given.
Time Frame
24 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: has laminectomy with instrumentation or equal or more than 3 levels laminectomy age 18-65 years ASA 1-3 elective operation Exclusion Criteria: allergy to tranexamic acid anemia (Hb<12 g/dl in female or Hb<13 g/dl in male) history of CVT, IHD, PE, strokes liver disease chronic kidney disease with creatinie>2.0 mg/dl receive anticoagulant or coagulopathy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Manee Raksakietisak, MD
Organizational Affiliation
Mahidol University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Manee Raksakietisak
City
Bangkok
ZIP/Postal Code
10700
Country
Thailand

12. IPD Sharing Statement

Learn more about this trial

Reduction Bleeding in Laminectomy With Double Doses of Tranexamic Acid

We'll reach out to this number within 24 hrs